Who should not use fezolinetant?

Although Fezolinetant is a non-hormonal drug, not all women are suitable for use. In clinical practice, certain underlying diseases or drug interactions may increase the risk of medication use and require strict screening of patients. First, fezonatant is contraindicated in women with known cirrhosis because the drug is primarily metabolized by the liver, and impaired liver function may cause the drug to accumulate in the body, thereby increasing the risk of toxicity and even causing severe liver damage. Secondly, patients with severe renal impairment or end-stage renal disease are not suitable to use this drug. Although the main metabolic pathway of fezonatant is the liver, some drugs and metabolites are excreted through the kidneys. Impaired renal function may lead to drug accumulation or increased side effects.

In addition, fezonatant should not be used concomitantly withCYP1A2 inhibitors. CYP1A2 is an important enzyme system for drug metabolism. Simultaneous use of inhibitors may lead to abnormal increases in the plasma concentration of fezonatant and increase the risk of adverse events, including hepatotoxicity and other systemic reactions. Therefore, patients who are taking CYP1A2 inhibitors should avoid concurrent use of fezonatant, or adjust the regimen under the guidance of a physician.

For women with a history of the above diseases or medications, a detailed medical history and laboratory evaluation should be performed before treatment to rule out potential risks. At the same time, for patients whose liver and kidney function status has not yet been determined, basic blood and biochemical tests should be performed first to ensure safety before starting medication. Even if you are eligible for medication, you should closely monitor liver and kidney function during treatment and pay attention to any abnormal symptoms at any time, such as jaundice, fatigue, or changes in urine output. If discomfort occurs, discontinue medication immediately and seek guidance.

Overall, fizonatant provides a new non-hormonal treatment option for relieving menopausal symptoms, but its safety depends on strict screening and monitoring. Identifying contraindication groups, following the doctor's guidance in medication use, and conducting regular follow-up are key measures to ensure efficacy and reduce risks.

Reference materials:https://www.veozah.com/